



Figure A4. Survival with respect to treatment regimen and *MGMT* promoter methylation.


A: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: concurrent temozolomide and no concurrent temozolomide.




B: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: adjuvant temozolomide and no adjuvant temozolomide.




C: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated:
concurrent temozolomide and no concurrent temozolomide.




D: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated:
adjuvant temozolomide and no adjuvant temozolomide.




E: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
concurrent temozolomide and no concurrent temozolomide.



F: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated: adjuvant temozolomide and no adjuvant temozolomide.



G: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
concurrent temozolomide and no concurrent temozolomide.



H: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
adjuvant temozolomide and no adjuvant temozolomide.

